Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
No more medications for diabetes
Researchers have found that differences in the GLP1RA gene , which encodes the GLP-1 receptor, influence how much weight someone is likely to lose on these medications
This translated into real outcomes in the SELECT trial , where semaglutide reduced heart attacks, strokes and cardiovascular deaths by around 20% in people with established heart disease without diabetes
If some patients are using food as a form of comfort or reward regulation, could the satiety and central effects of GLP-1 agonists reduce the drive toward other reward-seeking behaviours as well
A brief narrative review by Pantazopoulos, D., et al Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: A narrative review by Urbina, E., et al GLP receptor agonist use is associated with increased risk of osteoporosis, gout and osteomalacia in adults with Type 2 diabetes and obesity by Wajahath, M., et al Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension by Wilding, J.P.H., et al Nutrient Deficiency ebook by Chris Kresser Learn more about the Adapt Naturals Core Plus bundle, or take our quiz to see which products best suit your needs If youd like to ask a question for Chris to answer in a future episode, submit it here Hey everybody, Chris Kresser here
Lipotocin is selected by professionals for IV and IM wellness protocols supporting
